UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000039374
Receipt No. R000044771
Scientific Title The effects of intestinal flora on the development and prognosis of pulmonary nontuberculous mycobacteriosis.
Date of disclosure of the study information 2020/02/10
Last modified on 2020/02/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The effects of intestinal flora on the development and prognosis of pulmonary nontuberculous mycobacteriosis.
Acronym Relationship between intestinal flora and pulmonary nontuberculous mycobacteriosis.
Scientific Title The effects of intestinal flora on the development and prognosis of pulmonary nontuberculous mycobacteriosis.
Scientific Title:Acronym Relationship between intestinal flora and pulmonary nontuberculous mycobacteriosis.
Region
Japan

Condition
Condition Pulmonary nontuberculous mycobacteriosis
Classification by specialty
Pneumology Infectious disease
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To analyze the effects of intestinal flora on the development and prognosis of pulmonary nontuberculous mycobacteriosis.
Basic objectives2 Others
Basic objectives -Others To analyze the relationship between the therapeutic effect on pulmonary nontuberculous mycobacteriosis and the intestinal flora.
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Effects of intestinal flora on the development and prognosis of pulmonary nontuberculous mycobacteriosis.
Key secondary outcomes The relationship between therapeutic effects on pulmonary nontuberculous mycobacteriosis and intestinal flora.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Inpatient/Outpatient: unquestioned.
2. Patients with pulmonary opacities such as nodular shadow, granular shadow, bronchiectasis, cavity shadow, or infiltration witch are characteristic for pulmonary nontuberculous mycobacteriosis.
3. Patients who have been given sufficient explanations to participate in this study, and with sufficient understanding and who have given their informed consent.
Key exclusion criteria 1. Patients who have received antibiotic treatment within the last two months.
2. Patients judged to be inappropriate as research subjects by researchers.
Target sample size 100

Research contact person
Name of lead principal investigator
1st name Yoshifumi
Middle name
Last name Imamura
Organization Department of Respiratory Medicine
Division name Nagasaki University Hospital
Zip code 852-8501
Address 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki-ken
TEL 095-819-7273
Email yimamura@nagasaki-u.ac.jp

Public contact
Name of contact person
1st name Yoshifumi
Middle name
Last name Imamura
Organization Department of Respiratory Medicine
Division name Nagasaki University Hospital
Zip code 852-8501
Address 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki-ken
TEL 095-819-7273
Homepage URL
Email yimamura@nagasaki-u.ac.jp

Sponsor
Institute Nagasaki University
Institute
Department

Funding Source
Organization Japan Science and Technology Agency
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nagasaki University Hospital Clinical Research Ethics Committee
Address 1-7-1 Sakamoto, Nagasaki-shi, Nagasaki-ken
Tel 095-819-7229
Email gaibushikin@ml.nagasaki-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 02 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2019 Year 12 Month 26 Day
Date of IRB
Anticipated trial start date
2020 Year 02 Month 17 Day
Last follow-up date
2026 Year 12 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Patients with clinically suspected pulmonary Non-tuberculous mycobacteriosis (NTM) disease are to be entered and routinely examined to divide them into pulmonary NTM disease group and non-pulmonary NTM disease group. A case-control study will be conducted between these two groups. Stool collection will be performed at outpatient visits and at the time of hospitalization for the purpose of examination or induction of treatment, and the stool flora will be analyzed using the next-generation sequencer at the National Institute of Health Sciences, National Institute of Health Sciences and Nutrition. In addition, we will conduct surveys using questionnaires on patient background, eating habits, and lifestyle habits. For these collected items, we will compare the pulmonary NTM disease group with the non-pulmonary NTM disease group to analyze the relationship between the onset and treatment of pulmonary NTM disease and the intestinal flora.
In addition, for patients who started standard treatment for pulmonary NTM disease under normal medical care after participating in this study, 3 to 6 months after the start of treatment, the efficacy of treatment by chest CT examination and the change of intestinal microflora will be analyzed.

Management information
Registered date
2020 Year 02 Month 03 Day
Last modified on
2020 Year 02 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044771

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.